Imdusiran FDA Alignment Is Process, Not Proof: Class Efficacy Ceiling Looms Over Phase 2b

Arbutus Advances Imdusiran, Files LNP Patent Lawsuits, and Plans Shareholder Capital Return

Arbutus Biopharma reported its second quarter 2026 financial results, maintaining a strong financial position with $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026. The company received approximately $178 million from the Moderna settlement in July and announced plans to return up to $230 million in capital to shareholders. Additionally, Arbutus, along with Genevant Sciences, filed three international patent enforcement lawsuits against Pfizer and BioNTech related to LNP technology. The company also achieved alignment with the U.S. Food and Drug Administration (FDA) on the design for a proposed Phase 2b clinical trial for imdusiran, an investigational therapy for chronic hepatitis B.

• Arbutus reported a strong financial position with $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Following the $950 million noncontingent settlement with Moderna, Arbutus received its $178.4 million share in July 2026. The company plans to return up to approximately $230 million in capital to shareholders, potentially through a tender offer or open market purchases, commencing in Q3 2026.
• Arbutus, in collaboration with its exclusive licensee Genevant Sciences, initiated three international patent enforcement lawsuits against Pfizer, BioNTech, and their affiliates. These lawsuits, filed across 21 countries, aim to protect and defend Arbutus's patented lipid nanoparticle (LNP) technology, which is utilized in the defendants' COVID-19 vaccines, following a prior settlement agreement with Moderna.
• Significant progress was made in the clinical development of imdusiran (AB-729), Arbutus's RNAi therapeutic for chronic hepatitis B (cHBV). The U.S. FDA granted Fast Track designation for imdusiran in April 2026, recognizing its potential to address an unmet medical need. Furthermore, in May 2026, Arbutus reached alignment with the FDA on the design and safety parameters for a proposed Phase 2b clinical trial for imdusiran.

Fast Track for Imdusiran: Addressing cHBV's Unmet Needs

Current treatment approaches for chronic hepatitis B (cHBV) have made meaningful progress in viral suppression, yet fundamental virological and immunological barriers continue to impede durable disease control. The gap between viral suppression and functional cure remains the central unresolved challenge, underscoring the unmet need that novel therapeutic strategies must address.

• Inability to eliminate cccDNA: Licensed polymerase inhibitors target HBV reverse transcriptase activity and suppress viral replication during long-term therapy, but they fail to eliminate covalently closed circular DNA (cccDNA). This episomal minichromosome persists within the nucleus of infected hepatocytes and serves as the transcriptional template for all viral RNAs and proteins — including hepatitis B surface antigen (HBsAg) — ensuring viral persistence regardless of treatment duration.

• Limited functional cure rates: HBsAg seroclearance — the benchmark for functional cure — occurs in only 3–5% of patients after 10 years of nucleos(t)ide analog (NA) therapy, and in 8–14% within 3–5 years of pegylated interferon (PegIFNα) treatment. Because NAs cannot act on cccDNA, inhibiting or clearing HBsAg production remains an exceptionally difficult clinical objective.

• Post-treatment relapse: Even when functional cure is achieved with PegIFNα, durability is not guaranteed; more than 10% of patients experience virological relapse, with the majority occurring within 48 weeks following functional cure.

• Renal and bone safety concerns with long-term NA use: Chronic administration of tenofovir disoproxil fumarate (TDF) has been associated with reduced kidney function and loss of bone mineral density. Comparative data indicate that TDF carries a more pronounced adverse effect profile than tenofovir alafenamide (TAF) or entecavir (ETV) with respect to both renal and bone tissue outcomes, posing tolerability challenges for patients requiring lifelong therapy.

• Immunological barriers to viral clearance: HBV DNA integration into hepatocyte genomes, combined with compromised T cell function and insufficient B cell responses, creates a profoundly immunosuppressive microenvironment. Immune exhaustion and viral immune evasion are well-documented features of chronic infection, collectively limiting the host's capacity to achieve spontaneous or therapy-assisted HBV clearance.

Aligning with FDA on Imdusiran's Phase 2b Design

Clinical trials in chronic hepatitis B (CHB) span a range of therapeutic modalities — from nucleos(t)ide analogues to immunomodulatory agents — each evaluated across distinct virological, biochemical, and serological endpoints. The studies summarized below reflect the breadth of trial designs employed in this space, providing a reference framework relevant to structuring and benchmarking a Phase 2b program such as that for imdusiran.

Imdusiran's Potential in the Evolving cHBV Landscape

Over the past five years, the treatment paradigm for chronic hepatitis B (cHBV) has undergone a fundamental reorientation — moving away from indefinite viral suppression toward functional cure, defined as sustained HBsAg loss and undetectable serum HBV DNA. This shift has been driven by the recognition that spontaneous HBsAg loss occurs in only approximately 1% of HBsAg-positive individuals annually, with currently approved antivirals achieving functional cure in fewer than 1% of treated patients per year. In response, a wave of novel therapeutic modalities has entered clinical investigation, including small interfering RNAs (siRNAs), capsid assembly modulators (CAMs), core inhibitors, nucleic acid polymers (NAPs), and therapeutic vaccines — each targeting distinct steps in the HBV replication cycle.

Clinical trial data have begun to substantiate the promise of these approaches, particularly in combination regimens. Among siRNA agents, xalnesiran at 200 mg combined with pegylated interferon alfa-2a achieved HBsAg loss at 24 weeks post-treatment in 23% of participants, with HBsAg seroconversion in 20% — though responses were largely confined to patients with baseline HBsAg below 1,000 IU/mL. The CAM prodrug ALG-000184 has demonstrated unprecedented reductions in HBV DNA, RNA, and viral antigens across multiple trials, while the core inhibitor vebicorvir, in a phase II study, produced a significantly greater mean reduction in HBV DNA versus placebo when added to entecavir (−5.33 vs. −4.20 log IU/mL; p = 0.0084 at Week 24), along with superior pregenomic RNA suppression. The intranasal therapeutic vaccine CVP-NASVAC achieved functional cure in 9.5% of treated patients, with anti-HBs antibody detection rates reaching 58.3% in nucleos(t)ide analogue-naïve patients.

Parallel advances have also refined the safety profiles of established backbone therapies. Tenofovir alafenamide (TAF) has demonstrated stable or modestly improved renal function and bone mineral density over 96 weeks in Taiwanese CHB patients with renal or hepatic impairment, maintaining a 96% virologic suppression rate. The next-generation agent tenofovir amibufenamide (TMF) showed HBV DNA seroconversion rates of 90.5% versus TAF's 85.2% at 48 weeks, with lower serum creatinine levels, suggesting an improved renal tolerability profile. Taken together, the emerging clinical consensus favors combination strategies — integrating siRNAs, CAMs, or NAPs with nucleos(t)ide analogues and immunomodulatory agents — as the most viable path toward achieving functional cure at a meaningful population scale.

Arbutus Forges Ahead in HBV Cure and LNP IP

The recent update from Arbutus Biopharma paints a picture of a company strategically navigating two critical fronts: advancing a promising therapeutic candidate for chronic hepatitis B (HBV) and vigorously defending its foundational intellectual property in lipid nanoparticle (LNP) technology. The alignment with the FDA on a Phase 2b trial for imdusiran (AB-729), an investigational siRNA therapeutic, marks a significant step forward in addressing a global health challenge affecting 250 million people. Current standard-of-care agents offer low cure rates, primarily because the HBV cccDNA remains stable, allowing viral replication to resume upon treatment cessation. Imdusiran, by targeting viral RNAs, offers a novel mechanism to reduce HBsAg and viral replication, holding the potential for a functional cure, especially in combination approaches.

Simultaneously, the company's decision to file international patent enforcement lawsuits related to LNP technology underscores the immense value and strategic importance of these delivery systems. LNPs are the most widely employed platform for in vivo RNA delivery, critical for the success of mRNA vaccines and siRNA therapeutics. The outcome of these legal battles will significantly shape the landscape of RNA delivery platforms, potentially impacting future licensing revenues and market positioning. While the financial settlement provides a strong cash position and flexibility for continued pipeline development, the path forward is not without its considerations. The inherent challenges of achieving a functional cure for HBV mean that imdusiran's clinical success, despite promising preclinical data, is not guaranteed. Furthermore, the resolution of complex patent litigation is inherently uncertain, and unfavorable rulings could diminish the company's strategic leverage. As the company progresses, careful management of these clinical and legal pathways will be paramount to realizing the full potential of its assets in the evolving RNA therapeutics market.